» Articles » PMID: 39891862

Integrative Pan-cancer Genomic Analysis Highlights Mitochondrial Protein P32 As a Potential Therapeutic Target in Myc-driven Tumorigenesis

Overview
Journal Med Oncol
Publisher Springer
Date 2025 Feb 1
PMID 39891862
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor metabolic reprogramming, particularly involving mitochondrial metabolism, is a hallmark of malignancy. The mitochondrial protein p32 (C1QBP) has emerged as a critical regulator in various cancers, frequently associated with poor patient prognosis. However, the role of p32 across different cancer types remains largely unexplored. Our bioinformatics analysis demonstrates that p32 is significantly overexpressed in several malignancies and is closely involved in multiple oncogenic pathways related to tumor progression and metabolic reprogramming. Moreover, p32 expression positively correlates with genomic heterogeneity and drug sensitivity. We identified a strong association between p32 and c-Myc in both normal and cancerous tissues. We confirmed that p32 is a direct transcriptional target of c-Myc, which upregulates p32 by binding to its promoter. Functional experiments established that p32 is crucial for MYC-driven tumorigenesis, with its knockdown or knockout inhibiting tumor proliferation and extending survival. Targeting p32 may inhibit MYC-driven tumorigenesis, highlighting its potential as a therapeutic target in MYC-driven cancers.

References
1.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

2.
Anashkina A, Leberfarb E, Orlov Y . Recent Trends in Cancer Genomics and Bioinformatics Tools Development. Int J Mol Sci. 2021; 22(22). PMC: 8618360. DOI: 10.3390/ijms222212146. View

3.
Hsu C, Tseng L, Lee H . Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016; 241(12):1281-95. PMC: 4950268. DOI: 10.1177/1535370216641787. View

4.
Chiu H, Tay E, Ong D, Taneja R . Mitochondrial Dysfunction at the Center of Cancer Therapy. Antioxid Redox Signal. 2019; 32(5):309-330. DOI: 10.1089/ars.2019.7898. View

5.
Wang Q, Chai D, Sobhani N, Sun N, Neeli P, Zheng J . C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response. Front Physiol. 2022; 13:1012112. PMC: 9713694. DOI: 10.3389/fphys.2022.1012112. View